NasdaqGS - Nasdaq Real Time Price USD
Black Diamond Therapeutics, Inc. (BDTX)
As of 12:17 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | -0.37 | -0.35 | -1.44 | -1.35 |
| Low Estimate | -0.41 | -0.4 | -1.54 | -1.57 |
| High Estimate | -0.33 | -0.31 | -1.34 | -0.99 |
| Year Ago EPS | -0.45 | -0.34 | -1.88 | -1.44 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.49 | -0.47 | -0.43 | -0.39 |
| EPS Actual | -0.45 | -0.34 | -0.35 | -0.36 |
| Difference | 0.04 | 0.13 | 0.08 | 0.03 |
| Surprise % | 8.20% | 27.70% | 18.60% | 7.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.37 | -0.35 | -1.44 | -1.35 |
| 7 Days Ago | -0.37 | -0.35 | -1.44 | -1.36 |
| 30 Days Ago | -0.35 | -0.35 | -1.41 | -1.54 |
| 60 Days Ago | -0.35 | -0.34 | -1.4 | -1.54 |
| 90 Days Ago | -0.37 | -0.37 | -1.47 | -1.67 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | 3 |
| Up Last 30 Days | -- | 2 | 2 | 4 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | 2 | 2 | -- |
Growth Estimates
| CURRENCY IN USD | BDTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 17.80% | -- | -- | 4.40% |
| Next Qtr. | -2.90% | -- | -- | 7.80% |
| Current Year | 23.40% | -- | -- | 2.50% |
| Next Year | 6.20% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.89% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 10/9/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 10/8/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/24/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 9/23/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/18/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 9/10/2024 |
Related Tickers
STOK Stoke Therapeutics, Inc.
13.10
+3.23%
ALEC Alector, Inc.
5.30
+4.44%
PASG Passage Bio, Inc.
0.6128
+5.55%
PLRX Pliant Therapeutics, Inc.
14.49
+3.50%
CABA Cabaletta Bio, Inc.
4.3900
+1.39%
GOSS Gossamer Bio, Inc.
0.9735
+0.57%
RVMD Revolution Medicines, Inc.
50.34
+2.76%
NKTX Nkarta, Inc.
4.1050
+3.40%
EWTX Edgewise Therapeutics, Inc.
33.97
+2.96%
SGMT Sagimet Biosciences Inc.
5.78
+12.68%